NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients

Despite effective targeted therapy acting on KIT and PDGFRA tyrosine kinases, gastrointestinal stromal tumors (GIST) escape treatment by acquiring mutations conveying resistance to imatinib mesylate (IM). Following the identification of NKp30-based immunosurveillance of GIST and the off-target effec...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncoimmunology
Asıl Yazarlar: Rusakiewicz, Sylvie, Perier, Aurélie, Semeraro, Michaela, Pitt, Jonathan M., Pogge von Strandmann, Elke, Reiners, Katrin S., Aspeslagh, Sandrine, Pipéroglou, Christelle, Vély, Frédéric, Ivagnes, Alexandre, Jegou, Sarah, Halama, Niels, Chaigneau, Loic, Validire, Pierre, Christidis, Christos, Perniceni, Thierry, Landi, Bruno, Berger, Anne, Isambert, Nicolas, Domont, Julien, Bonvalot, Sylvie, Terrier, Philippe, Adam, Julien, Coindre, Jean-Michel, Emile, Jean-François, Poirier-Colame, Vichnou, Chaba, Kariman, Rocha, Benedita, Caignard, Anne, Toubert, Antoine, Enot, David, Koch, Joachim, Marabelle, Aurélien, Lambert, Marion, Caillat-Zucman, Sophie, Leyvraz, Serge, Auclair, Christian, Vivier, Eric, Eggermont, Alexander, Borg, Christophe, Blay, Jean-Yves, Le Cesne, Axel, Mir, Olivier, Zitvogel, Laurence
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Taylor & Francis 2016
Konular:
Original Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5283614/
https://ncbi.nlm.nih.gov/pubmed/28197361
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1137418
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller